KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) EPS (Basic) (2016 - 2025)

Jazz Pharmaceuticals has reported EPS (Basic) over the past 16 years, most recently at $3.34 for Q4 2025.

  • Quarterly results put EPS (Basic) at $3.34 for Q4 2025, up 6.71% from a year ago — trailing twelve months through Dec 2025 was -$4.26 (down 146.92% YoY), and the annual figure for FY2025 was -$5.84, down 164.46%.
  • EPS (Basic) for Q4 2025 was $3.34 at Jazz Pharmaceuticals, down from $4.14 in the prior quarter.
  • Over the last five years, EPS (Basic) for JAZZ hit a ceiling of $4.14 in Q3 2025 and a floor of -$11.74 in Q2 2025.
  • Median EPS (Basic) over the past 5 years was $1.09 (2023), compared with a mean of $0.13.
  • Biggest five-year swings in EPS (Basic): crashed 612.96% in 2022 and later soared 3533.33% in 2023.
  • Jazz Pharmaceuticals' EPS (Basic) stood at -$0.54 in 2021, then crashed by 612.96% to -$3.85 in 2022, then skyrocketed by 138.96% to $1.5 in 2023, then soared by 108.67% to $3.13 in 2024, then increased by 6.71% to $3.34 in 2025.
  • The last three reported values for EPS (Basic) were $3.34 (Q4 2025), $4.14 (Q3 2025), and -$11.74 (Q2 2025) per Business Quant data.